Assessing the efficacy and safety of sequential intravesical gemcitabine and docetaxel – does time from transurethral resection of bladder tumour to induction matter?
Open Access
- 21 March 2025
- journal article
- Published by Wiley in BJU International
- Vol. 136 (1) , 42-44
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 AmendmentJournal of Urology, 2024
- Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non–muscle-invasive Bladder CancerEuropean Urology Oncology, 2023
- Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non–Muscle-Invasive Bladder CancerJAMA Network Open, 2023
- Prognostic Implications of Treatment Delays for Patients with Non–muscle-invasive Bladder CancerEuropean Urology Focus, 2022
- European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)European Urology, 2022
- Time interval from transurethral resection of bladder tumour to bacille Calmette–Guérin induction does not impact therapeutic responseBJU International, 2021
- Delaying BCG immunotherapy onset after transurethral resection of non-muscle-invasive bladder cancer is associated with adverse survival outcomesWorld Journal of Urology, 2020
- Systemic Absorption and Pharmacokinetics of Single-dose Intravesical Gemcitabine After Transurethral Resection of the Bladder in Non-muscle-invasive Bladder CancerUrology, 2009